A phase II study of bisantrene in advanced refractory breast cancer. An Eastern Cooperative Oncology Group pilot study.

Abstract

Thirty patients with advanced refractory breast cancer received bisantrene 260 mg/m2 intravenously every 3 weeks. Reversible myelosuppression was the most commonly observed side effect. Four patients (13.3%) achieved objective partial response (90% confidence intervals 3-24%), while two patients (6.6%) had disease improvement with a PR + IMP rate of 19.9%. Seven additional patients (23.3%) had stabilization of disease. This drug has antitumor activity against breast cancer and warrants further study, particularly if problems with drug delivery are overcome.

• Authors: K J Pandya, F M Muggia, R T Skeel, G Falkson, B M Kaplan, D S Ettinger
• Journal: American journal of clinical oncology (Am J Clin Oncol) Vol. 8 Issue 5 Pg. 353-7 (Oct 1985) ISSN: 0277-3732 [Print] United States
• PMID: 4061372 (Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Anthracenes
• bisantrene

Topics

• Adult
• Aged
• Anthracenes (therapeutic use, toxicity)
• Breast Neoplasms (drug therapy)
• Drug Evaluation
• Female
• Humans
• Leukopenia (chemically induced)
• Middle Aged
• Pilot Projects